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Partial removal of monocytes from human peripheral blood mononuclear cells, or the addition of indometh- 
acin. reduced the antiproliferative effect of 1,25(OH),D, on mitogen-stimulated mononuclear cells. Addition 
of 1,25(OH),D, (I nM) to mitogen-stimulated mononuclear cells caused a 2-4-fold increase in prostaglandin 
E, production during the second day of culture. The inhibitory effect of 1,25(OH),D, on lymphocyte prolif- 
eration is greatly augmented up to 7-fold in the presence of prostaglandin E,. We conclude that monocytes 
are involved in the inhrbitory effect of 1,25(OH),D, on the mitogenic stimulation of human lymphocytes 
and that their action is probably mediated by prostaglandins. 
I .?.5-Dihydroqvitamin D, Prostaglandin E Monocyte Lymphocyte activation 
1. INTRODUCTION 
1,25(OH)aDs induces the differentiation and 
maturation of malignant and normal cells of the 
monocytic lineage at various stages of their devel- 
opment [ 11. 1,25(OH)zD3 enhances macrophage 
functions like oxygen radical formation, phago- 
cytosis and lymphokine-induced monokine pro- 
duction [1,2]. The hormone inhibits mitogen and 
antigen-induced T cell proliferation and antibody 
secretion by B cells [3-61. The inhibitory effect of 
1,25(OH)~D3 on T cell activation is associated with 
inhibition of both the production and the response 
to interleukin 2 [3,4] and is dependent upon the 
Abbreviations: 1,25(OH)~D3, 1,25dihydroxyvitamin 
D3; PHA, phytohemagglutinin; ConA, concanavalin A; 
PGE2, prostaglandin E2; PBM, peripheral blood mono- 
nuclear 
presence of high-affinity receptors for 
1,25(OH)zD3 [7]. Receptors for 1,25(OH)zD3 are 
present in monocytes and in mitogen-activated 
peripheral blood human lymphocytes [8]. The pro- 
liferative response of T cells to mitogens in a PBM 
cell preparation involves the interaction of ac- 
cessory cells, mainly monocytes, with the lympho- 
cytes. However, monocytes may produce factors 
like prostaglandins, leukotrienes and oxygen 
radicals which inhibit lymphocyte proliferation 
[9, lo]. The inhibition of mitogen-induced PBM 
cell stimulation by 1,25(OH)zD3 may be mediated 
by effects on the regulatory monocytes and/or the 
effector T lymphocytes. 
2. MATERIALS AND METHODS 
2.1. Materials 
Purified PHA was obtained from Wellcome Re- 
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search Laboratories, Bekenham, England. ConA, 
2 x crystallized was from Bio Yeda, Rehovot, 
Israel. 1,25(OWD3 was obtained from 
Hoffmann-LaRoche, Nutley, NJ (a gift from Dr 
M. Uskokovic). Indomethacin and PGE2 were 
from Sigma Chemicals. [methyf-3H]Thymidine 
(2 Ci/mmol) was from Nuclear Research Center 
Negev, Beer-Sheva, Israel and [3H]PGE2 from 
New England Nuclear, Boston, MA, USA. 
2.2. Cell preparation and culture conditions 
Buffy coats from the Beilinson Medical Center 
Blood Bank were used as a source for human PBM 
cells. PBM cells were separated by Ficoll-Hypaque 
density gradient centrifugation [7]. Partial deple- 
tion of adherent cells was achieved by incubating 
PBM cells (5 x 106/ml) for 90 min at 37°C in 
RPMI-1640 medium containing 2qo heat- 
inactivated fetal calf serum in plastic petri dishes. 
Monocyte content of PBM cells was thus reduced 
from -20 to -6% and the yield of the non- 
adherent cells was about 50%. Cell culture and 
mitogenic stimulation conditions were as described 
[7]. PHA (1 @g/ml), ConA (10 pg/ml), indo- 
methacin, 1,25(OH)~D3 and PGEz were added at 
the initiation of the culture. [3H]Thymidine 
(1 &i/well) was added at 68 h and the cells were 
harvested 4 h later. PGEz was determined in condi- 
tioned media obtained by culturing PBM cells 
(2 x 106/ml) in growth medium for 48 h. ConA 
(10 pg/ml) or PHA (1 ,ug/ml) or 1,25(OH)2Ds 
(1 nM) were added at zero time. Indomethacin 
(10 pg/ml) was added at zero time or at 24 h. Cells 
were cultured in 24 well plates (1 ml/well). 
2.3. Determination of PGEz 
PGE2 was determined in 0.1 ml aliquots of con- 
ditioned media by radioimmunoassay as described 
[ 111, using a specific rat antibody that has a cross- 
reactivity of < 1% with all major PGs (Bio Yeda, 
Rehovot, Israel). 
3. RESULTS 
PBM cells were stimulated with PHA in the 
presence or absence of 1,25(OH)zDs (1 nM). The 
hormone significantly inhibited the mitogen- 
induced DNA synthesis (fig.1). Partial removal of 
adherent cells resulted in a decrease in the in- 
hibitory effect of the hormone in nine out of 
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twelve donors. The extent of inhibition for the 
twelve donors was reduced from 42 + 2.9 to 
22 f 3.9% (mean f SE) (fig.1). Adherent cells 
may participate in the 1,25(0H)2Ds_dependent i - 
hibition of lymphocyte proliferation by the pro- 
duction of PGE. This thesis was investigated by 
studying the effect of 1,25(OH)zDs in the presence 
or absence of the cyclooxygenase inhibitor indo- 
methacin. The inhibitor was used at a concentra- 
tion (5 pg/ml) which was found, in preliminary ex- 
periments, to inhibit PGE2 production by more 
than 90%. Indomethacin did not affect PHA- 
induced mitogenic stimulation of PBM cells, but 
PBM Adhomntca PBM Pm 
Dm +hamm 
Fig. 1. The effect of adherent cell depletion and in- 
domethacin on the response of PBM cells to 
1,25(OH)pD3. Mononuclear cells were partially depleted 
of adherent cells and cultured for 72 h with PHA (1 
@g/ml) in presence or absence of 1,25(OH)zD3 (1 nM) 
(left panel). In another series of experiments, PHA- 
stimulated PBM cells were cultured in the presence or 
absence of indomethacin (5 pg/ml) and/or 1,25(OH)zD3 
(1 nM). All experiments were done in triplicate cultures. 
The effect of 1,25(OH)~D3 on thymidine incorporation 
in treated cultures was expressed as percent inhibition of 
control cultures. Each line represents a different experi- 
ment performed on cells from a different donor. 
Statistical analysis was done by paired t-test. 
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significantly 0, < 0.01) reduced the inhibitory ef- 
fect of 1,25(OH)zDs from 43 f 2.3 to 28 + 3.8% 
(fig.1). No such effect was observed in cultures 
depleted of adherent cells (not shown). A similar 
effect of indomethacin was observed when ConA 
served as a mitogen (inhibition of DNA synthesis 
was reduced from 53 + 4 to 36 + 6070, mean + 
SE). We conclude from these results that adherent 
cells are involved in the inhibitory action of 
1,25(OH)~Dx on lymphocyte proliferation prob- 
ably via indomethacin-sensitive pathway(s). 
The next experiments, were performed in order 
to find out whether 1,25(OH)zD3 affects the pro- 
duction of PGE2. PGE2 concentrations in 48 h 
cultures of mitogen-stimulated PBM cells are 
significantly higher in the presence of 1,25(OH)zD3 
(table 1). The addition of indomethacin (10 pg/ml) 
at the initiation of cultures abolished the produc- 
tion of PGE2. Assuming that the addition of indo- 
methacin at 24 h blocks PGE2 production in the se- 
cond day of culture, PGE2 accumulation during 
the first day can be determined irectly and during 
the second day calculated by subtraction. No effect 
of 1,25(OH)~D3 on PGE;? accumulated uring the 
first day of culture could be observed (table 1). On 
the other hand, 1,25(OH)zD3 increased the ac- 
Table 1 
Additions PGEz (ng/106 cells) in conditioned 
media of PBM cells cultured with 
Oh 24 h None 1,25(OH)zD3 
ConA - 2.21 * 0.39 6.41 k 1.65 
@<O.O1)b 
ConA+ - 0.02 
indomet 
ConA indomet 0.89 f 0.10 
PHA - 2.52 & 0.63 
ND 
1.12 + 0.39 (NS) 
4.64 f 0.48 
@<O.Ol) 
PHA+ - ND” 
indomet 
PHA indomet 0.92 + 0.09 
“ND, non-detectable 
0.07 
1.28 f 0.70 (NS) 
bSignificance of the effect of 1,25(OH)zDj as judged by 
the unpaired r-test. NS, non-significant 
PBM cells were cultured for 48 h in the presence of 
mitogen. 1,25(OH)zD3 (1 nM) was added at time zero 
and indomethacin (lOgg/ml) at time zero or at 24 h. All 
cultures were performed in quadruplicates and the 
results presented as mean f SD 
cumulation of PGE2 during the second day of 
culture from 1.3 to 5.3 ng/106 cells in the ConA 
and from 1.6 to 3.4 ng/106 cells in the PHA- 
stimulation systems. To find out whether 
1,25(0H)zD3-dependent inhibition of lymphocyte 
proliferation was affected by PGE2, PBM cells 
depleted of adherent cells were stimulated with op- 
timal concentration of PHA in the presence of 
various concentrations of PGE2 and 1,25(OH)zD3 
(fig.2). Under these experimental conditions PGE2 
alone did not affect the rate of DNA synthesis. 
However, the presence of PGE2 potentiated up to 
7-fold the inhibitory effect of 1,25(OH)zD3. 
4. DISCUSSION 
The results of this work support the notion that 
monocytes, probably via the production of prosta- 
glandins, are responsible at least partially for the 
inhibitory effect of 1,25(OH)zD3 on the mitogen- 
stimulated human PBM cells. This conclusion is 
based upon the following findings: partial deple- 
tion of monocytes, by plastic adherence, resulted 
in a diminished inhibitory effect of 1,25(OH)zD3 
on lymphocyte proliferation. A similar effect was 
produced by blocking prostaglandin synthesis in 
PBM cell cultures, but not in cultures depleted of 
monocytes . 
Fig.2. The effect of 1,25(OH)zDs and PGEz on lym- 
phocyte proliferation. PBM cells were partially depleted 
of adherent cells and cultured in the presence of PHA 
and various concentrations of PGEz and/or 
1,25(OH)~D3. The results are presented as the mean f 
SD of triplicate cultures. 
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Prostaglandins may be involved in the mediation 
of 1,25(OH)zD3 action by two mechanisms: 
(i) 1,25(OH)zDj may enhance the production 
of monocyte-derived prostaglandins; (ii) 
1,25(OH)2Ds and prostaglandins may act 
synergistically to inhibit lymphocyte stimulation. 
Our findings that 1,25(OH)zDs increases the pro- 
duction of PGE2 and that its effect is potentiated 
by PGE2 demonstrate that both mechanisms may 
operate. Furthermore, the concentrations of PGE2 
produced in the presence of 1,25(OH)zD3 are of 
the same order of magnitude as those which poten- 
tiate the effect of 1,25(OH)zD3. PGE2 is known to 
activate adenylate cyclase. Although the 
mechanism of the cooperation between PGE2 and 
1,25(OH)zD3 is not known, it most probably does 
not involve a 1,25(OH)zD3_mediated increase in 
cyclic AMP production, since it has been shown 
that 1,25(OH)zD3 attenuates rather than increases 
cyclic AMP accumulation in activated human T 
lymphocytes [ 121. 
The interactions between 1,25(OH)zD3 and 
PGE2 demonstrated in this study may suggest hat 
the hormone has a modulatory role in other pro- 
cesses which involve prostaglandins, like inflam- 
mation. The finding that 1,25(OH)zD3 enhances 
the production of PGE2 by monocytes may have a 
direct bearing on the well documented bone resor- 
bing acitivity of the hormone, since there is 
evidence that monocytes stimulate osteoclastic- 
bone resorption, an effect mediated by pros- 
taglandins [ 131. 
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